Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland

Pharmacogenetics

Volumn 7, Issue 1, 1997, Pages 65-71

  Syvänen, Ann Christine ^a   Tilgmann, Carola ^b   Rinne, Juha ^c   Ulmanen, Ismo ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

catechol O methyltransferase; enzyme activity; genetic polymorphism; Parkinson's disease

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FINLAND; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; POPULATION; PRIORITY JOURNAL;

CATECHOL O-METHYLTRANSFERASE; DNA; DNA PRIMERS; ENZYME STABILITY; ERYTHROCYTES; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HEAT; HUMANS; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REFERENCE VALUES; VARIATION (GENETICS);

PARKINSONIA;

EID: 0030904954     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199702000-00009     Document Type: Article

References (38)

1. Agundez JAG, Jiminez-Jiminez FJ, Luengo A. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995: 57, 291-298.
2. Armstrong M, Daly AK, Cholerton, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. The Lancet 1992: 339, 1017-1018.
3. Batt AM, Magdalou J, Vincent-Viry M, Ouzzine M, Fournel-Gigleux S, Galteau MM, Siest G. Drug metabolizing enzymes related to laboratory medicine: cytochromes P-450 and UDP-glucuronosyltransferases. Clin Chim Acta 1994: 226, 171-190.
4. Bertocci B, Miggiano V, Da Prada M, Dembic Z, Lahm H-W, Malherbe P. Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc Natl Acad Sci USA 1991: 88, 1416-1420.
5. Boudikova B, Szumlanski C, Maidak B, Weìshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 1990: 48, 381-389.
6. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976: 72, 248-254.
7. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Medicine 1995: 73, 539-553.
8. Floderus Y, Ross SB, Wetterberg L. Erythrocyte catechol-O-methyltransferase activity in a Swedish population. Clin Genet 1981: 19, 389-392.
9. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potentials. Clin Pharmacokinet 1994: 26, 59-70.
10. Grossman M, Emanuel B, Budarf M. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q1 1.1-q11.2. Genomics 1992a: 12, 822-825.
11. Grossman MH, Littrel JB, Weinstein R, Szumlanski CL, Weinshilboum RM. Identification of the possible molecular basis for inherited differences in human calechol-O-methyltransferase. Soc Neurosci (Abstr.) 1992b: 18, 70.
12. Higuchi R. Simple and rapid preparation of samples for PCR. In: Erlich HA, ed. PCR technology - principles and applications for DNA amplification. New York: Stockton, 1989: 31-39.
13. Ho SL, Ramsden DB, Kapadi AL, Sturman SG, Williams AC. Activity and polymorphism of monoamine oxidase-B (MAO-B) gene in Parkinson's disease. Biogenic Amines 1994: 10, 579-585.
14. Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase-B in Parkinson's disease. Annals Neurol 1995a: 37, 403-405.
15. Ho SL, McCann KP, Bennett P, Kapadi AL, Waring RH, Ramsden DB, Williams AC. The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Adv Neurol 1995b: 69, 53-60.
16. Kaakkola S, Gordin A, Männistö P. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994: 25, 813-824.
17. Klemetsdal B, Straume B, Giverhaug T, Aarbakke J. Low catecholO-methyltransferase activity in a Saami population. Eur J Pharmacol 1994: 46, 231-235.
18. Kopin I. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 1985: 37, 334-364.
19. Lotta T, Vidgren J, Tilgmann C et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995: 34, 4202-4210.
20. Lundström K, Salminen M, Jalanko A, Savolainen R, Ulmanen I. Cloning and characterization of human placental catecholO-methyltransferase cDNA. DNA Cell Biol 1991: 10, 206-212.
21. Lundström K, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Ulmanen I. Cloning, expression and structure of catechol-O-methyltransferase. Biochem Biophys Acta 1995: 1251, 1-10.
22. McLeod HL, Fang L., Luo X, Scott EP, Evans WE. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 1994: 270, 26-29.
23. Meyer UA. Pharmacogenetics: the slow, the rapid and the ultrarapid. Proc Natl Acad Sci USA 1994: 91, 1983-1984.
24. Männistö P, Ulmanen I, Lundström K, et al. Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Progr Drug Res 1992: 39, 291-350.
25. Männistö P, Ulmanen I, Taskinen J, Kaakkola S. Catechol-O-methyltransferase (COMT) and COMT inhibitors. In: Sandler M, Smith HJ eds. Design of enzyme inhibitors as drugs. Vol. 2. Oxford: Oxford Science Press, 1994: 624-646.
26. Reilly DK, Rivera-Calimlim L, Van Dyke D. Catechol-0-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 1980: 28, 278-286.
27. Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltranferase activity between orientals and caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 1983: 35, 804-809.
28. Scanlon PD, Raymond FA, Weishilboum RM. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 1979: 203, 63-65.
29. Schultz E, Nissinen E, Kaakkola S. Determination of catechol-O-methyltranferase activity in erythrocytes by high performance chromatography with electrochemical detection. Biomed Chromatogr 1989: 3, 64-67.
30. Smit N, Pavel S, Kammeyer A, Westerhof W. Determination of catechol-O-methyltransferase activity in relation to melanin metabolism using high performance liquid chromatography with fluorimetric detection. Anal Biochem 1990: 190, 286-291.
31. Smith CA, Gough AC, Ieigh NP et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. The Lancet 1992: 339, 1375-1377.
32. Spielman RS, Weishilboum RM. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet 1981: 10, 279-290.
33. Syvänen A-C, Aalto-Setälä K, Harju L, Kontula K, Söderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990: 8, 684-692.
34. Syvänen A-C, Sajantila A, Lukka M. Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet 1993: 52, 46-59.
35. Tanner CM. Epidemiology of Parkinson's disease, Neurol Clin 1992: 10, 317-329.
36. Tenhunen J, Salminen M, Lundström K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol-O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994: 223, 1049-1059.
37. Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol-O-methyltransferase. Nature 1994: 368, 354-358.
38. Winqvist R, Lundström K, Salminen M, Laatikainen M, Ulmanen I. The human catechol-O-methyltransferase gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BgII. Cytogenet Cell Genet 1992: 59, 253-257.